A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: Role of visceral fat

BACKGROUND: Empagliflozin, a sodium glucose cotransporter 2 inhibitor, is a medication to treat type 2 diabetes. The effect of empagliflozin in persons without diabetes has received less attention. Here we conducted a randomized, double-blind placebo-controlled clinical trial to examine the effect o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Min Hee, Neeland, Ian J., de Albuquerque Rocha, Natalia, Hughes, Connor, Malloy, Craig R., Jin, Eunsook S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728102/
https://www.ncbi.nlm.nih.gov/pubmed/35024596
http://dx.doi.org/10.1016/j.metop.2021.100161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728102/
https://www.ncbi.nlm.nih.gov/pubmed/35024596
http://dx.doi.org/10.1016/j.metop.2021.100161

Ejemplares similares